Biomedical subjects

F Mamdani

Publications and source records attributed to F Mamdani.

3 recordsLinked to original sources

PubMed2004

Pharmacogenetics and bipolar disorder.

Bipolar disorder (BD) is a major psychiatric condition that commonly requires prophylactic and episodic treatment. There is important variability in the therapeutic response and side-effect profiles to currently available pharmacological agents. Pharmacogenetics have provided new hopes to develop more efficient treatment strategies tailored to the individual patient's needs. This review assesses nonsystematically studies using pharmacogenetic strategies in BD. Most of these studies have focused on patients selected according to lithium response, and more recently, a growing number of studies have been investigating genetic factors in mixed samples of patients classified according to response to antidepressant treatment. Although previous clinical and family studies support the use of pharmacogenetic strategies both to increase phenotype homogeneity as well as to identify genetic factors that may mediate response to treatment, most molecular studies carried out to date are still preliminary and in need of external validation. A major problem has been comparability between studies, in part, because of differences in the criteria used to define response. More attention should be paid to standardize the criteria for drug response definition.

Antidepressive Agents↗

PubMed1995

Ciprofloxacin use under a reserved drug and stepdown promotion program.

This study retrospectively evaluated the use of parenteral ciprofloxacin (PC) under the influence of a reserved antimicrobial drug program and an intravenous-oral stepdown program. During the first three months following its formulary introduction, 92 PC treatment courses were initiated. Fifty of these treatment courses in 49 adults were randomly selected for study. The hematology service accounted for 50% of the courses reviewed. The balance were initiated in the intensive care unit (16%), and six other services (34%). PC was used for the treatment of febrile neutropenia (50%), respiratory tract infections (20%), gram-negative sepsis (10%), and five other indications. Initial use of the intravenous formulation was considered appropriate in 92% of courses. Stepdown therapy occurred in 17 (34%) of treatment courses. Of the 26 patients considered candidates for oral therapy, seven patients (27%) were eligible for earlier stepdown and nine patients (35%) did not receive oral drug. According to our criteria, unnecessary use of the intravenous route occurred in 20% of PC treatment days. Mean total cost (acquisition plus delivery) of therapy per course was $668. This cost was higher in the hematology service (mean $990) than any other service (p = 0.0015). When stepdown therapy was employed the mean daily cost of therapy was $43.63 vs. $55.61 when the oral dosage form was not used (p = 0.04). Parenteral drug costs totalling $6245 were avoided by subsequent use of the oral dosage form. If full compliance with stepdown criteria had occurred, an estimated total savings of $10,769 could have been realized.

Adult↗

PubMedDate not supplied

Development and implementation of simplified aminoglycoside empiric dosing guidelines.

Poor empiric dosing of aminoglycosides continues to be a problem in many hospitals. Consequently, a two-phase study was undertaken to evaluate gentamicin and tobramycin (G-T) dosing in our institution and to develop practical guidelines to achieve optimum initial G-T serum concentrations. In the pre-intervention phase (phase 1), approximately one-third of 232 G-T treatment courses were initiated with regimens that resulted in low initial serum concentrations. Empiric dosing guidelines were subsequently developed using Pharmacy Pharmacokinetic Service data and literature recommendations. They were validated with patients in phase 1. Compared with earlier dosing methods, the guidelines resulted in initial serum G-T concentrations within the therapeutic range in an equivalent proportion of patients. To simplify the procedure, recommended dosages were based on age, total weight, and serum creatinine only. The guidelines were tabular in format, and prescriber calculations were not required. Pocket and wall chart guidelines were distributed and promoted. During the post-intervention phase (phase 2), the impact of the guidelines was assessed. A review of 232 phase 1 and 203 phase 2 treatment courses revealed an increase in the initial mean dose per interval prescribed after the intervention (p < 0.01). No change in the mean interval was noted. When guidelines were followed, a higher proportion of treatment courses achieved early therapeutic serum concentrations (Cpmax 5-10 mg/L, 80% vs 54%; p < 0.005). The new empiric guidelines appear to be a practical alternative to existing methods of dosing aminoglycosides.

Adult↗